We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Chlorin e6 – polyvinylpyrrolidone mediated photosensitization is effective against human non-small cell lung carcinoma compared to small cell lung carcinoma xenografts
© Chin et al; licensee BioMed Central Ltd. 2007
Received: 09 July 2007
Accepted: 01 December 2007
Published: 01 December 2007
Photodynamic therapy (PDT) is an effective local cancer treatment that involves light activation of a photosensitizer, resulting in oxygen-dependent, free radical-mediated cell death. Little is known about the comparative efficacy of PDT in treating non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), despite ongoing clinical trials treating lung cancers. The present study evaluated the potential use of chlorin e6 – polyvinylpyrrolidone (Ce6-PVP) as a multimodality photosensitizer for fluorescence detection and photodynamic therapy (PDT) on NSCLC and SCLC xenografts.
Human NSCLC (NCI-H460) and SCLC (NCI-H526) tumor cell lines were used to establish tumor xenografts in the chick chorioallantoic membrane (CAM) model as well as in the Balb/c nude mice. In the CAM model, Ce6-PVP was applied topically (1.0 mg/kg) and fluorescence intensity was charted at various time points. Tumor-bearing mice were given intravenous administration of Ce6-PVP (2.0 mg/kg) and laser irradiation at 665 nm (fluence of 150 J/cm2 and fluence rate of 125 mW/cm2). Tumor response was evaluated at 48 h post PDT. Studies of temporal fluorescence pharmacokinetics in CAM tumor xenografts showed that Ce6-PVP has a selective localization and a good accuracy in demarcating NSCLC compared to SCLC from normal surrounding CAM after 3 h post drug administration. Irradiation at 3 h drug-light interval showed greater tumor necrosis against human NSCLC xenografts in nude mice. SCLC xenografts were observed to express resistance to photosensitization with Ce6-PVP.
The formulation of Ce6-PVP is distinctly advantageous as a diagnostic and therapeutic agent for fluorescence diagnosis and PDT of NSCLC.
Photodynamic therapy (PDT) is a promising modality in both the curative and palliative treatment against a variety of experimental and naturally occurring human cancers . Essentially, PDT is a two-step process that begins with the administration of photosensitizer for selective uptake in the target tissue. The second phase involves exposure to non-thermal light at a wavelength specific to the photosensitizer at the sensitized target tissue. The activation of the photosensitizer by light is an oxygen-dependent process that results in the generation of highly cytotoxic species including singlet oxygen. The release of these reactive molecules results in damage to both tumor cells and to the tumor microenvironment. The significance of PDT is that there is a degree of treatment selectivity that allows tumor destruction with minimal involvement of healthy tissue. This is achieved by a combination of selective accumulation of photosensitizer within the tumor and by control of the light geometry and illumination parameters .
Lung cancer became one of the first cancers to be considered for PDT and has been used as an adjuvant treatment over the last 27 years . Currently, PDT is used either to treat microinvasive endobronchial non-small cell lung carcinoma (NSCLC) or to palliate patients with completely or partially obstructing endobronchial NSCLC . Despite the generally refractory nature of these type of tumors, central type of tumors with identifiable endobronchial lesions which could be easily accessed bronchoscopically for illumination have been successfully treated with PDT . PDT can preserve lung function, limiting surgical trauma and postoperative pain as well as used in combination with other therapeutic modalities such as chemotherapy . Photosensitizer-induced fluorescence detection aimed at enhancing optical contrast to improve tumor visibility has been extensively investigated to develop 'tumor selective' imaging methods [6, 7]. The lack of tumor selectivity, complex pharmacokinetics and the fact that some photosensitizers may cause prolonged skin photosensitivity, make the clinical application of fluorescence detection and PDT more complex [8, 9]. These limitations have led to the development of second-generation photosensitizers, which usually produce shorter periods of photosensitivity, longer activation wavelengths, higher tumor-to-normal tissue concentration, excellent antitumor effect and higher quantum yields of 1O2 . Studies showed that derivatives from chlorophylls/chlorins are potent photosensitizers [11, 12], of which mono-L-aspartyl chlorin e6 (NPe6, Laserphyrin) is undergoing clinical trials in Japan for the treatment of endobronchial lung cancer .
Results and discussion
A comparison of areas under the ROC curves between NSCLC and SCLC at various time post drug administration.
Time post Ce6 – PVP administration, h
Area under the ROC curve
Area under the ROC curve
Almost all PDT studies were concerned with NSCLC due to the referral patterns in the clinics . Although PDT has also been shown to be effective in the clinical treatment of SCLC , little preclinical data exist comparing the efficacy or tendency for resistance toward photosensitization between these two tumor histologies. In this study, we observed a certain degree of resistance to PDT in SCLC xenografts that could be related to faster elimination rate of Ce6-PVP, which resulted in lower cellular accumulation of the photosensitizer. There are already a variety of molecular markers that have been implicated in the pathogenesis of SCLC  thus making it difficult to hypothesize the molecular basis of acquired resistance towards photosensitization in our experiments. Generally, in lung cancer four types of multidrug resistance have been identified, i.e., classical multidrug resistance (MDR), non-P-glycoprotein MDR (also called MRP), atypical MDR (mediated through altered expression of topoisomerases II) and lung resistance-related protein . Previous evidence indicates that SCLC cell lines and tumors express multidrug resistance-associated protein, i.e. MRP1, ATP binding cassette [ABC]C1  and ABCG2 (ATP-binding cassette protein for breast cancer resistance protein) . Hence, one plausible reason to explain the lack of activity of Ce6-PVP in SCLC is the possible existence of ABC transporters of chlorin-based (tetrapyrrole) photosensitizers in this tumor histology. The importance of human ABCG2 in the transport of tetrapyrrole structure has been implicated . It was reported that cancer cell lines that expresses ABCG2 was found to efflux some of the chlorophyll based photosensitizers and thus may confer resistance to this treatment modality [27, 28]. It has been suggested that by inhibiting ABCG2 transport using tyrosine kinase inhibitors (e.g. Gleevec), it is likely to be a more successful approach to enhancing clinical PDT .
Photosensitization with Ce6-PVP for 3 hours of exposure time appeared to be most effective in detecting NSCLC in CAM model. Furthermore, PDT at 3 h drug-light interval resulted in a better tumor necrosis in NSCLC xenograft model. SCLC xenografts were found to manifest a certain degree of resistance to photosensitization with Ce6-PVP. Despite the limited activity of Ce6-PVP in the SCLC xenografts, it is conceivable that the combined modality of fluorescence imaging and targeted photodynamic therapy using Ce6-PVP may still have a potential role in SCLC. This warrants for additional studies on the molecular mechanisms of photosensitization resistance in SCLC to overcome this important clinical problem.
Ce6-PVP was manufactured by ORPEGEN Pharma GmbH, Heidelberg, Germany. It is a co-lyophilisate of chlorin e6 (Ce6) and polyvinypyrrolidone (PVP, molecular mass ≈ 12,000) in a 1:1 mass ratio. A working concentration of 0.03 mM of Ce6-PVP was prepared using phosphate buffered saline to measure the absorption spectra. 1 ml of the solution was placed in a cuvette and the absorbance was measured from 300 – 800 nm. Absorption spectra were recorded on a spectrofluorophotometer RF-5301 PC (Shimadzu, Japan).
The NCI-H460 cell line originates from human carcinoma of the large cell lung cancer. NCI-H526 cell lines originate from human carcinoma of the lung from the variant small cell lung cancer were obtained from the American Type Culture Collection, USA. NCI-H460 cells were cultured as a monolayer whereas NCI-H526 cells were cultured in suspension in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% non-essential amino acids (Gibco, USA), 1% sodium pyruvate (Gibco, USA), 100 units/ml penicillin/streptomycin (Gibco, USA) and incubated at 37°C, 95% humidity and 5% CO2. Before inoculation, the monolayer cells were washed with phosphate-buffered saline, trypsinized, and counted using a haemacytometer. Suspension cells were directly counted using a haemacytometer without trypsinization.
CAM tumor xenograft
Fertilized chicken eggs were incubated at 37°C in a humidified atmosphere inside a hatching incubator equipped with an automatic rotator (Octagon 20, Brinsea, Somerset, UK). At embryo age (EA) 7, a window of about 1.5 cm was opened in the eggshell to detach the shell membrane from the developing CAM. Then, the window was sealed with sterilized parafilm to avoid contamination and the eggs were returned to the static incubator for further incubation until the day of experiments. On EA 9, approximately 5 × 106 NCI-H460 and NCI-H526 cells were inoculated on the CAM. The window of the eggs were resealed with sterile parafilm and returned to the static incubator. Grafted cells were allowed to grow on the CAM for up to 5 days. On EA 14, Ce6-PVP was dissolved in 0.9% sodium chloride (B. Braun Medical Inc, USA) to constitute a stock solution of 1 mg/mL. The stock solution was further diluted to obtain a volume of 80 μL containing a dose of 1 mg/kg body weight of the chick's embryo. The photosensitizer was applied on the entire surface of the CAM and left to incubate for 30 min. The window was resealed to avoid evaporation of the drug solution from the CAM. After 30 min incubation, imaging was performed at 0.5, 1, 2, 3, 4, 5, 6, and 24 h post drug administration. All procedures involving preparation and administration of the photosensitizer were conducted under low ambient lighting.
Fluorescence images were performed using the Karl Storz D-light fluorescence endoscopy system (Karl Storz, Tuttlingen, Germany). This D-light system consisted of xenon short arc lamp, filtered by a band pass filter (370 – 450 nm) to excite Ce6-PVP and a sensitive colour CCD video camera connected to a modified endoscope integrated with long pass filter (cut-off wavelength at 560 nm). The red channel registered the photosensitizer's fluorescence and the blue channel captured the diffusely back-scattered excitation light. The intensities of the red and blue channels of the fluorescence images were quantified using the software MicroImage (Olympus Optical Co. (Europa), Germany). The red-to-blue intensity ratio of the fluorescence endoscopic image algorithm was found to be effective in separating benign tissue from dysplasia, and carcinoma in situ/squamous cell carcinoma from dysplasia . By applying the red-to-blue intensity ratio as a diagnostic algorithm, the intensities of the red fluorescence of Ce6-PVP are determined as a function of time. Such algorithm is independent of the geometries of excitation/collection of signals and the power of excitation during the fluorescence imaging process .
Statistical analysis of fluorescence image
To statistically evaluate the temporal fluorescence of Ce6-PVP, logistic regression and receiver operating characteristics (ROC) curve  was determined using the GraphPad software for Windows (GraphPad, San Diego, CA). The elimination rate constant of Ce6-PVP was calculated by a method fitting the data to a one-phase exponential decay equation. The validity of fitted curve was verified with the test of runs (F test) in each case. Area under the curve (AUC), P value, and cut-off point were obtained from the ROC curve. The area under the ROC curve measures accuracy of the fluorescence images. The accuracy of the ROC curve analysis is based on how well the fluorescence images discriminates the tumor region from the normal CAM, as defined by white light imaging. The closer the curve follows the left border and then the top border of the ROC space, the more accurate the test. The closer the curve comes to the 45-degree diagonal of the ROC space, the less accurate the test. In addition, likelihood ratios (where the likelihood ratio is defined as the ratio of the probability of the fluorescence signal for tumor to the probability of the fluorescence signal for normal region) were calculated to help determine the 'best' cut-off point to compare sensitivity and specificity between NSCLC and SCLC.
PDT treatment on murine xenograft model
Male Balb/c athymic (nu+/nu+) (ARC, WA, Australia) mice were used for tumor xenografting at the age of 8–10 weeks. Approximately 3.0 × 106 NCI-H460 and NCI-H526 cells suspended in 150 μl of Hank's buffered saline solution were injected subcutaneously into both lower flanks of the mice. The animals were used for experiments when the tumors measured a surface diameter around 7 – 10 mm. A dose of 2.0 mg/kg of the photosensitizer was administered intravenously through the tail vein. The mice were anaesthetized with 50 μl cocktail of ketamine hydrochloride (50 mg/ml, Trittau, Germany) and valium (1:1 vol/vol) through intraperitoneal injection. A diode laser (Ceralas PDT 665, Biolitec) emitting at a wavelength of 665 ± 3 nm was used for irradiation. The peak power output was calibrated to 1.65 W at the fiber tip before commencement of irradiation. The laser energy with a total fluence of 150 J/cm2 was delivered to a 1.0 cm2 circular spot on the surface of the tumor via a silica fiber frontal light distributor (FD model, Medlight, Switzerland). Fluence rate of 125 mW/cm2 was measured using a power meter (LaserCheck, Coherent, USA). PDT treatment was performed at 3 and 6 h drug-light interval on one tumor while the contralateral tumor that was not irradiated served as controls. All procedures were approved by the national experimental animal welfare institution (Institutional Animal Care and Use Committee, SingHealth, Singapore), in accordance with international standards.
Macroscopic assessment of tumor response post PDT
At 48 h post PDT, 1% Evans Blue (Merck, Germany) in PBS was injected intraperitoneally at a volume of 0.4 mL in mice for examination of viable or necrotic tissues at post PDT. Six hours later, animals were sacrificed and the tumors were excised. Around 2–3 mm thick cross-section slices were cut in a plane parallel to the direction of incident light and imaged under a stereoscopic microscope (Stemi 2000C, Zeiss, Germany). The unstained area was attributed to tissue necrosis, whereas the blue stained area indicated viable tissue. Digital images were all analyzed using NIH Image v1.62 software. Each image captured had the same calibration values to allow uniformity in the processing of the images. The tumor was outlined using the freehand drawing tool to measure the total tumor area. Similarly the necrotic area of the tumor was measured. The percentage of necrosis was calculated as the necrotic area divided by the total tumor area multiplied by 100. Statistical analysis (Student's t test) was used for multiple comparisons. The criterion for statistical significance was set at the 0.05 level.
We thank HAEMATO-science GmbH, Germany for providing the photosensitizer; Dr Othmar Dill (Target, GmbH, Germany) for reading the manuscript and National Medical Research Council Singapore for funding the research work. WWC is the recipient of Singapore Millennium Foundation Scholarship 2007.
- Pervaiz S, Olivo M: Art and science of photodynamic therapy. Clin Exp Pharmacol Physiol. 2006, 33 (5-6): 551-556. 10.1111/j.1440-1681.2006.04406.x.View ArticlePubMedGoogle Scholar
- van den Bergh H: On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy. 1998, 30 (4): 392-407.View ArticlePubMedGoogle Scholar
- Moghissi K, Dixon K: Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?. Eur Respir J. 2003, 22 (3): 535-541. 10.1183/09031936.03.00005203.View ArticlePubMedGoogle Scholar
- Maziak DE, Markman BR, MacKay JA, Evans WK: Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg. 2004, 77 (4): 1484-1491. 10.1016/j.athoracsur.2003.07.017.View ArticlePubMedGoogle Scholar
- Moghissi K: Role of bronchoscopic photodynamic therapy in lung cancer management. Curr Opin Pulm Med. 2004, 10 (4): 256-260. 10.1097/01.mcp.0000128434.57020.6a.View ArticlePubMedGoogle Scholar
- Sutedja TG, Venmans BJ, Smit EF, Postmus PE: Fluorescence bronchoscopy for early detection of lung cancer: a clinical perspective. Lung Cancer. 2001, 34 (2): 157-168. 10.1016/S0169-5002(01)00242-2.View ArticlePubMedGoogle Scholar
- Piotrowski WJ, Gorski P: Photodynamic diagnosis and treatment of bronchial cancer. Int J Occup Med Environ Health. 2003, 16 (2): 105-112.PubMedGoogle Scholar
- Levy JG: Photosensitizers in photodynamic therapy. Semin Oncol. 1994, 21 (6 Suppl 15): 4-10.PubMedGoogle Scholar
- Lam S: Photodynamic therapy of lung cancer. Semin Oncol. 1994, 21 (6 Suppl 15): 15-19.PubMedGoogle Scholar
- Nyman ES, Hynninen PH: Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B. 2004, 73 (1-2): 1-28. 10.1016/j.jphotobiol.2003.10.002.View ArticlePubMedGoogle Scholar
- Pandey RK, Bellnier DA, Smith KM, Dougherty TJ: Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy. Photochem Photobiol. 1991, 53 (1): 65-72.View ArticlePubMedGoogle Scholar
- Pandey RK, Goswami LN, Chen Y, Gryshuk A, Missert JR, Oseroff A, Dougherty TJ: Nature: a rich source for developing multifunctional agents. Tumor-imaging and photodynamic therapy. Lasers Surg Med. 2006, 38 (5): 445-467. 10.1002/lsm.20352.View ArticlePubMedGoogle Scholar
- Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T: Photodynamic therapy (PDT) for lung cancers. J Thorac Oncol. 2006, 1 (5): 489-493.View ArticlePubMedGoogle Scholar
- Chin WW, Lau WK, Heng PW, Bhuvaneswari R, Olivo M: Fluorescence imaging and phototoxicity effects of new formulation of chlorin e6-polyvinylpyrrolidone. J Photochem Photobiol B. 2006, 84 (2): 103-110.View ArticlePubMedGoogle Scholar
- Ramaswamy B, Manivasager V, Chin WW, Soo KC, Olivo M: Photodynamic diagnosis of a human nasopharyngeal carcinoma xenograft model using the novel Chlorin e6 photosensitizer Fotolon. Int J Oncol. 2005, 26 (6): 1501-1506.PubMedGoogle Scholar
- Chin WW, Heng PW, Bhuvaneswari R, Lau WK, Olivo M: The potential application of chlorin e6-polyvinylpyrrolidone formulation in photodynamic therapy. Photochem Photobiol Sci. 2006, 5 (11): 1031-1037. 10.1039/b605772a.View ArticlePubMedGoogle Scholar
- Chin WW, Lau WK, Bhuvaneswari R, Heng PW, Olivo M: Chlorin e6-polyvinylpyrrolidone as a fluorescent marker for fluorescence diagnosis of human bladder cancer implanted on the chick chorioallantoic membrane model. Cancer Lett. 2007, 245 (1-2): 127-133. 10.1016/j.canlet.2005.12.041.View ArticlePubMedGoogle Scholar
- Thong PS, Ong KW, Goh NS, Kho KW, Manivasager V, Bhuvaneswari R, Olivo M, Soo KC: Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007, 8 (10): 950-952. 10.1016/S1470-2045(07)70318-2.View ArticlePubMedGoogle Scholar
- Lam S, Kennedy T, Unger M, Miller YE, Gelmont D, Rusch V, Gipe B, Howard D, LeRiche JC, Coldman A, Gazdar AF: Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest. 1998, 113 (3): 696-702.View ArticlePubMedGoogle Scholar
- Chin W, Lau W, Lay SL, Wei KK, Olivo M: Photodynamic-induced vascular damage of the chick chorioallantoic membrane model using perylenequinones. Int J Oncol. 2004, 25 (4): 887-891.PubMedGoogle Scholar
- Kubota K, Furuse K, Kawaguchi T, Kawahara M, Ogawara M, Yamamoto S: A case of long-term survival with stage IV small cell lung cancer and early-stage central-type squamous cell lung cancer treated by photodynamic therapy. Jpn J Clin Oncol. 1999, 29 (1): 45-48. 10.1093/jjco/29.1.45.View ArticlePubMedGoogle Scholar
- Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol. 1998, 16 (3): 1207-1217.PubMedGoogle Scholar
- Scagliotti GV, Novello S, Selvaggi G: Multidrug resistance in non-small-cell lung cancer. Ann Oncol. 1999, 10 Suppl 5: S83-6.View ArticlePubMedGoogle Scholar
- Modok S, Mellor HR, Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006, 6 (4): 350-354. 10.1016/j.coph.2006.01.009.View ArticlePubMedGoogle Scholar
- Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S: Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res. 2003, 9 (8): 3052-3057.PubMedGoogle Scholar
- Tamura A, Watanabe M, Saito H, Nakagawa H, Kamachi T, Okura I, Ishikawa T: Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol. 2006, 70 (1): 287-296.PubMedGoogle Scholar
- Robey RW, Steadman K, Polgar O, Bates SE: ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther. 2005, 4 (2): 187-194.View ArticlePubMedGoogle Scholar
- Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, Bates SE: Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004, 64 (4): 1242-1246. 10.1158/0008-5472.CAN-03-3298.View ArticlePubMedGoogle Scholar
- Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, Oseroff AR: The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007, 13 (8): 2463-2470. 10.1158/1078-0432.CCR-06-1599.View ArticlePubMedGoogle Scholar
- Andersson-Engels S, Klinteberg C, Svanberg K, Svanberg S: In vivo fluorescence imaging for tissue diagnostics. Phys Med Biol. 1997, 42 (5): 815-824. 10.1088/0031-9155/42/5/006.View ArticlePubMedGoogle Scholar
- Zheng W, Olivo M, Soo KC: The use of digitized endoscopic imaging of 5-ALA-induced PPIX fluorescence to detect and diagnose oral premalignant and malignant lesions in vivo. Int J Cancer. 2004, 110 (2): 295-300. 10.1002/ijc.20080.View ArticlePubMedGoogle Scholar
- Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983, 148 (3): 839-843.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.